GlobeNewswire

Articles of Association, Seluxit A/S

Share

Articles of Association, Seluxit A/S

Company Announcement No. 15 
Aalborg, 23. October 2019 

Articles of Association, Seluxit A/S.

Following the completion of the registration with the Danish Commerce and Companies Agency (Erhvervsstyrelsen), attached you find the updated articles of association containing the changes which were decided at Seluxit A / S 'annual general meeting on October 22, 2019

For further information, please contact CEO Daniel Lux.

You can subscribe to our investor newsletter on https://www.seluxit.com/investors and get company announcements directly in your mail box. You can also follow news from Seluxit on


Seluxit A/S
Hjulmagervej 32B
9000 Aalborg
Denmark
Tel.: +45 46 922 722
E-mail: investor@seluxit.com
Web: www.seluxit.com
CVR/VAT nr. 29388237
Certified Adviser
Norden CEF ApS, V/ John Norden
Kongevejen 365, 2840 Holte
Denmark
Tel.: +45 20 720 200
E-mail: jn@nordencef.dk
Web: www.nordencef.dk
CVR/VAT nr. 31933048

About Seluxit:
Seluxit is an Internet of Things (IoT) solution provider. We help product manufacturers connect their physical products to the Internet, and benefit from the value of data.  Seluxit’s vision is to be a major contributor to the story of the Internet of Things — how we humans can orchestrate connected products to improve our lives, while preserving our security and privacy.

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Recording of the Latvijas Gaze 3 months 2020 Investor Conference Webinar29.5.2020 07:40:00 CESTPress release

On May 28 JSC “Latvijas Gāze” organized its Investor Conference Online Webinar. During the webinar the Vice-Chairman of Management Board Sebastian Groeblinghoff analyzed “Latvijas Gāze” Group’s unaudited financial results of 3 months 2020 and informed about other key initiatives of the Group. The recorded webinar is available online: https://bit.ly/36Atahd, and the presentation, demonstrated during the webinar, is available in the attachment. Additional information: Madara Ventere Head of Finance and accounting division Phone: + (371) 67 369 281 E-mail: investor.relations@lg.lv www.lg.lv Attachment 2020-05-28_Latvijas Gaze Unaudited Q1 Results 2020_Investor_Webinar

Radisson Hospitality AB’s Q1 2020 Report29.5.2020 07:30:00 CESTPress release

January–March 2020 First Quarter 2020 Revenue decreased by MEUR 42.8 (–20.1%) to MEUR 170.6. The decrease is due to the negative impact of the COVID-19 outbreak. At the end of the quarter, 170 hotels were closed due to the pandemic. On a like-for-like basis, including hotels under renovation (“LFL&R”), Revenue decreased by MEUR 41.7 (–20.1%).Reported RevPAR for leased and managed hotels decreased by 20.7%. RevPAR LFL&R decreased by 20.1%.EBITDA decreased by MEUR 30.5 to MEUR –5.3. The results in March was severely impacted by the revenue drop due to COVID-19. The cost base was significantly reduced in the hotels as of March, while the full impact of the measures taken to reduce central costs is only visible as from April. The EBITDA margin was –3.1% (11.8%).EBIT decreased by MEUR 34.5 to MEUR –27.4. In addition to the EBITDA decrease, results are impacted by costs for depreciation on the new IT platform and investments in the leased properties in 2019. The EBIT margin was –16.1% (3.3%)

ObsEva SA to present at the Jefferies Virtual Healthcare Conference June 3rd, 202029.5.2020 07:00:00 CESTPress release

Geneva, Switzerland and Boston, MA – May 29, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that CEO Ernest Loumaye will present an update on the Company and its pipeline at the Jefferies Virtual Healthcare Conference taking place June 2-4, 2020. Mr. Loumaye’s presentation will take place on Wednesday June 3, 2020 at 8:00 a.m. Eastern Time (ET). A live presentation link will be available under “Events Calendar” in the investors section of ObsEva’s website at www.ObsEva.com About ObsEva ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor, and improving ET outcomes

Updated data demonstrate Roche’s Alecensa increases overall survival rate for people with ALK-positive non-small cell lung cancer29.5.2020 07:00:00 CESTPress release

ALEX study is the first global phase III study to show a clinically meaningful benefit in overall survival at five years (62.5% with Alecensa), compared with crizotinib (45.5%)Data confirm longer-term efficacy of Alecensa, both in patients with or without central nervous system metastases at baseline Basel, 29 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today presented updated data from the pivotal phase III ALEX study, showing an increased five-year survival rate with Alecensa® (alectinib), compared with crizotinib, in people living with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). These data confirm the longer-term efficacy of Alecensa already demonstrated across three phase III clinical trials. Full findings were presented at the ASCO20 Virtual Scientific Programme, on 29 May 2020. “These data further support Alecensa as the standard of care for people with metastatic ALK-positive NSCLC,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Offic

Yara prices US dollar bond offering28.5.2020 22:10:36 CESTPress release

Oslo, 28 May 2020: Yara International ASA today priced a new 10-year bond offering of USD 750 million (the “Notes”). The bond offering will be issued pursuant to Rule 144A/Regulation S. The bonds have a coupon of 3.148% per annum. Yara intends to use the net proceeds of the new issue for general corporate purposes as well as to repay certain existing indebtedness. Moody's and Standard & Poor's have assigned a rating to the bonds of Baa2 (stable) and BBB (stable), respectively. Contact Thor Giæver, Head of Investor Relations Mobile: (+47) 480 75 356 E-mail: thor.giaver@yara.com Nina Kleiv, Head of Finance, Treasury & Insurance Mobile: (+47) 414 40 067 E-mail: nina.kleiv@yara.com Liv Bergh, Head of Funding Mobile: (+47) 414 02 153 E-mail: liv.bergh@yara.com Cautionary Statements This press release is for information purposes only and does not constitute any offer to sell or the solicitation of an offer to buy any security in the United States or in any other jurisdiction. The Notes have

Galapagos increases share capital through subscription right exercises28.5.2020 22:01:00 CESTPress release

Mechelen, Belgium; 28 May 2020, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises. Galapagos issued 435,540 new ordinary shares on 28 May 2020, for a total capital increase (including issuance premium) of €17,914,162.40. CEO Onno van de Stolpe exercised 40,000 subscription rights. Four other management board members exercised an aggregate number of 345,000 subscription rights. In addition, one member of the supervisory board exercised 2,520 subscription rights. In accordance with Belgian transparency legislation1, Galapagos notes that its total share capital currently amounts to €352,968,964.92, the total number of securities conferring voting rights amounts to 65,254,562, which is also the total number of voting rights (the “denominator”), and all securities conferring voting rights and all voting rights are of the same category. The total number of rights (formerly known as warrants)